In the Boardroom
Refine Search
Biotechnology
The UK’s BioIndustry Association (BIA) chairwoman Dr Jane Osbourn has announced this week that she is to leave AstraZeneca after 25 years with Cambridge Antibody Technology and MedImmune, where she is vice president R&D and site leader, the trade group announced yesterday. 19 February 2019
Biotechnology
UK-based Emergex Vaccines has secured a research and development (R&D) facility and hired a chief scientific officer (CSO). 18 February 2019
Pharmaceutical
Mundipharma has appointed Patrice Grand as European director of corporate communications, reporting to Alberto Martinez, president and chief executive in Europe. 18 February 2019
Pharmaceutical
Spanish family-owned drugmaker Esteve has appointed Jordi Muntañola as the new chief commercial officer for Europe, taking on the leadership of all the pharmaceutical activities in Spain and Europe. 15 February 2019
Pharmaceutical
Privately-held French drugmaker Pierre Fabre Group has appointed Maarten Kraan to the position of director of research and development for Pierre Fabre Pharmaceuticals (PFM), reporting to Frédéric Duchesne, chief executive of the Pharmaceuticals Division, and will sit on the branch’s executive committee. 8 February 2019
Pharmaceutical
Appaloosa, the US hedge fund managed by billionaire David Tepper, has called for major and immediate change at Allergan, the Ireland-based drugmaker that is best known for its Botox (onabotulinumtoxinA) product. 6 February 2019
Biotechnology
Dutch biopharma Kiadis Pharma has announced the appointment of Robert Friesen as chief scientific officer (CSO) effective February 1, 2019. 5 February 2019
Biotechnology
Swiss pharma giant Roche’s Genentech subsidiary has appointed Alexander Hardy as chief executive, effective March 1, 2019. 25 January 2019
Biotechnology
Sangamo Therapeutics has appointed Adrian Woolfson as executive vice president of R&D, effective January 22, 2019. 23 January 2019
Pharmaceutical
The man leading the UK and Ireland operations in what Takeda calls the company’s ‘new phase’ will be Jon Neal, it has been confirmed. 22 January 2019
Pharmaceutical
Danish CNS specialist Lundbeck today announced that it has appointed Dr Johan Luthman as executive vice president and head of R&D. 22 January 2019
Pharmaceutical
Sir Philip Hampton, who since 2015 has been the non-executive chairman of GlaxoSmithKline, will step down from the role with the UK drugmaker. 21 January 2019
Biotechnology
UK-based T cell receptor (TCR) biotech firm Immunocore today named David Berman as its new head of research and development. 16 January 2019
Generics
Perrigo today announced that James Dillard has been appointed executive vice president and chief scientific officer. 14 January 2019
Pharmaceutical
Some four months after resigning from his role as physician-in-chief at Memorial Sloan Kettering Cancer Center (MSK) and stepping down from the board of US pharma major Bristol-Myers Squibb, José Baselga has been given another chance. 7 January 2019
Pharmaceutical
Peter Guenter has sought to keep up the pace of his turnaround of Spanish dermatology specialist Almirall. 4 January 2019
Pharmaceutical
US biopharma major AbbVie and Tizona Therapeutics, a privately-held immunotherapy company, have entered into a global, strategic collaboration to develop and commercialize CD39-targeted therapeutics, including TTX-030, a first-in-class antibody for the treatment of cancer. 3 January 2019
Biotechnology
UK clinical-stage biopharma firm Verona Pharma today announced the expansion of its global clinical development team with the appointment of Kathleen Rickard as chief medical officer, and Tara Rheault as vice president of R&D operations and global project management. 3 January 2019
Pharmaceutical
Recently-established Roivant Sciences company Altavant Sciences, which is focused on clinical development of novel therapies for pulmonary arterial hypertension and other indications, today announced the appointment of Lyn Baranowski as chief operating officer. 2 January 2019
Pharmaceutical
Swiss pharma giant Novartis announced today that Susanne Schaffert, currently president of its Advanced Accelerator Applications (AAA) business, has been appointed chief executive of Novartis Oncology. 20 December 2018
Biotechnology
US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
Anthony Harnden has been appointed as the new chair of the UK’s Medicine and Healthcare products Regulatory Agency (MHRA). 20 November 2024
Biotechnology
Mirai Bio has announced the appointment of Jens Vogel as the company’s president and chief operating officer (COO). 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Pharmaceutical
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Biotechnology
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
Biotechnology
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
Pharmaceutical
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
Biotechnology
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Biotechnology
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Biotechnology
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Biotechnology
US biotech major Biogen revealed it has appointed Daniel Quirk as chief medical officer and head of medical affairs. 29 October 2024
Pharmaceutical
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Biotechnology
AAVantgarde has announced the appointment of Lauren Kaskiel as chief business officer (CBO). 22 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze